Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
anti-inflammatory
Biotech
NodThera's NLRP3 inhibitor shows obesity promise in early trial
A readout from a phase 1b/2a study in humans with obesity has again demonstrated the drug’s anti-inflammatory potential.
James Waldron
Jun 12, 2024 7:00am
AbbVie pays $48M for OSE's preclinical chronic inflammation drug
Feb 28, 2024 5:25am
Union says phase 2 results show psoriasis hopeful has wider use
Jun 21, 2023 10:42am
AbbVie links up with VC firm to map anti-inflammatory companies
Nov 28, 2022 7:30am
Acelyrin brings total raised in 1 year past past $500M mark
Sep 13, 2022 10:05am
Inflammation space swells as Nuvig exits stealth mode with $47M
May 11, 2022 9:05am